Johnson & Johnson (JNJ) Payables (2009 - 2026)
Johnson & Johnson (JNJ) posted Payables of $27.9 billion for Q1 2026, up 36.29% sequentially from $20.5 billion in Q4 2025, and up 19.1% YoY from $23.4 billion in Q1 2025.
Johnson & Johnson (JNJ) Payables (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Payables data on file, last reported at $27.9 billion in Q1 2026.
- Quarterly Payables rose 19.1% year-over-year to $27.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.9 billion (up 19.1% YoY) and the FY2025 annual result came in at $20.5 billion, up 25.73% from the prior year.
- Payables rose to $27.9 billion in Q1 2026 per JNJ's latest filing, from $20.5 billion in the prior quarter.
- The five-year high for Payables was $27.9 billion in Q1 2026, with the low at $12.2 billion in Q4 2023.
- Average Payables over 5 years is $18.3 billion, with a median of $16.5 billion recorded in 2024.
- The widest YoY moves for Payables: up 104.97% in 2023, down 42.23% in 2023.
- Johnson & Johnson's Payables stood at $14.6 billion in 2022, then dropped by 10.25% to $13.1 billion in 2023, then gained by 24.54% to $16.3 billion in 2024, then advanced by 25.73% to $20.5 billion in 2025, then jumped by 36.29% to $27.9 billion in 2026.
- Business Quant data shows JNJ's Payables at $27.9 billion in Q1 2026, $20.5 billion in Q4 2025, and $16.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.03 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 27.92 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.77 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -22.55 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 6.01 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 358.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 27.92 Bn |
| Dec 28, 2025 | 20.49 Bn |
| Sep 28, 2025 | 16.01 Bn |
| Jun 29, 2025 | 20.99 Bn |
| Mar 30, 2025 | 23.44 Bn |
| Dec 29, 2024 | 16.29 Bn |
| Sep 29, 2024 | 13.42 Bn |
| Jun 30, 2024 | 18.70 Bn |
| Mar 31, 2024 | 16.72 Bn |
| Dec 31, 2023 | 13.08 Bn |
| Oct 1, 2023 | 12.23 Bn |
| Jul 2, 2023 | 22.14 Bn |
| Apr 2, 2023 | 27.89 Bn |
| Jan 1, 2023 | 22.65 Bn |
| Oct 2, 2022 | 14.58 Bn |
| Jul 3, 2022 | 14.07 Bn |
| Apr 3, 2022 | 13.61 Bn |
| Jan 2, 2022 | 14.82 Bn |
| Oct 3, 2021 | 12.76 Bn |
| Jul 4, 2021 | 11.88 Bn |